BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Liu X, Qin S. Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: Opportunities and Challenges. Oncologist 2019;24:S3-S10. [PMID: 30819826 DOI: 10.1634/theoncologist.2019-IO-S1-s01] [Cited by in Crossref: 24] [Cited by in F6Publishing: 34] [Article Influence: 12.0] [Reference Citation Analysis]
Number Citing Articles
1 Lee HW, Cho KJ, Park JY. Current Status and Future Direction of Immunotherapy in Hepatocellular Carcinoma: What Do the Data Suggest? Immune Netw 2020;20:e11. [PMID: 32158599 DOI: 10.4110/in.2020.20.e11] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 9.5] [Reference Citation Analysis]
2 Biglow L, Ashraf S, Alsharedi M. Checkpoint inhibitors: literature review of new treatments for hepatocellular carcinoma. Stem Cell Investig 2021;8:22. [PMID: 34917675 DOI: 10.21037/sci-2021-029] [Reference Citation Analysis]
3 Wang W, Pan F, Lin X, Yuan J, Tao C, Wang R. Ferroptosis-Related Hub Genes in Hepatocellular Carcinoma: Prognostic Signature, Immune-Related, and Drug Resistance Analysis. Front Genet 2022;13:907331. [DOI: 10.3389/fgene.2022.907331] [Reference Citation Analysis]
4 Pourhamzeh M, Asadian S, Mirzaei H, Minaei A, Shahriari E, Shpichka A, Es HA, Timashev P, Hassan M, Vosough M. Novel antigens for targeted radioimmunotherapy in hepatocellular carcinoma. Mol Cell Biochem 2022. [PMID: 35708866 DOI: 10.1007/s11010-022-04483-4] [Reference Citation Analysis]
5 Onuma AE, Zhang H, Huang H, Williams TM, Noonan A, Tsung A. Immune Checkpoint Inhibitors in Hepatocellular Cancer: Current Understanding on Mechanisms of Resistance and Biomarkers of Response to Treatment. Gene Expr 2020;20:53-65. [PMID: 32340652 DOI: 10.3727/105221620X15880179864121] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 7.0] [Reference Citation Analysis]
6 Sangro B, Melero I, Wadhawan S, Finn RS, Abou-Alfa GK, Cheng AL, Yau T, Furuse J, Park JW, Boyd Z, Tang HT, Shen Y, Tschaika M, Neely J, El-Khoueiry A. Association of inflammatory biomarkers with clinical outcomes in nivolumab-treated patients with advanced hepatocellular carcinoma. J Hepatol. 2020;73:1460-1469. [PMID: 32710922 DOI: 10.1016/j.jhep.2020.07.026] [Cited by in Crossref: 32] [Cited by in F6Publishing: 40] [Article Influence: 16.0] [Reference Citation Analysis]
7 Zheng L, Fang S, Wu F, Chen W, Chen M, Weng Q, Wu X, Song J, Zhao Z, Ji J. Efficacy and Safety of TACE Combined With Sorafenib Plus Immune Checkpoint Inhibitors for the Treatment of Intermediate and Advanced TACE-Refractory Hepatocellular Carcinoma: A Retrospective Study. Front Mol Biosci 2020;7:609322. [PMID: 33521054 DOI: 10.3389/fmolb.2020.609322] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Piñeiro Fernández J, Luddy KA, Harmon C, O'Farrelly C. Hepatic Tumor Microenvironments and Effects on NK Cell Phenotype and Function. Int J Mol Sci 2019;20:E4131. [PMID: 31450598 DOI: 10.3390/ijms20174131] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 7.7] [Reference Citation Analysis]
9 He Q, Yang J, Jin Y. Development and Validation of TACE Refractoriness-Related Diagnostic and Prognostic Scores and Characterization of Tumor Microenvironment Infiltration in Hepatocellular Carcinoma. Front Immunol 2022;13:869993. [PMID: 35493518 DOI: 10.3389/fimmu.2022.869993] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Yang J, He X, Lv Q, Jing J, Shi H. Management of Adverse Events in Cancer Patients Treated With PD-1/PD-L1 Blockade: Focus on Asian Populations. Front Pharmacol 2019;10:726. [PMID: 31312140 DOI: 10.3389/fphar.2019.00726] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
11 Kim JE, Kim E, Lee JW. TM4SF5-Mediated Regulation of Hepatocyte Transporters during Metabolic Liver Diseases. IJMS 2022;23:8387. [DOI: 10.3390/ijms23158387] [Reference Citation Analysis]
12 Zhang B, Tang B, Lv J, Gao J, Qin L. Systematic analyses to explore immune gene sets-based signature in hepatocellular carcinoma, in which IGF2BP3 contributes to tumor progression. Clin Immunol 2022;241:109073. [PMID: 35817291 DOI: 10.1016/j.clim.2022.109073] [Reference Citation Analysis]
13 Tang W, Chen Z, Zhang W, Cheng Y, Zhang B, Wu F, Wang Q, Wang S, Rong D, Reiter FP, De Toni EN, Wang X. The mechanisms of sorafenib resistance in hepatocellular carcinoma: theoretical basis and therapeutic aspects. Signal Transduct Target Ther 2020;5:87. [PMID: 32532960 DOI: 10.1038/s41392-020-0187-x] [Cited by in Crossref: 35] [Cited by in F6Publishing: 37] [Article Influence: 17.5] [Reference Citation Analysis]
14 Montella L, Sarno F, Ambrosino A, Facchini S, D'Antò M, Laterza MM, Fasano M, Quarata E, Ranucci RAN, Altucci L, Berretta M, Facchini G. The Role of Immunotherapy in a Tolerogenic Environment: Current and Future Perspectives for Hepatocellular Carcinoma. Cells 2021;10:1909. [PMID: 34440678 DOI: 10.3390/cells10081909] [Reference Citation Analysis]
15 Kooshkaki O, Derakhshani A, Hosseinkhani N, Torabi M, Safaei S, Brunetti O, Racanelli V, Silvestris N, Baradaran B. Combination of Ipilimumab and Nivolumab in Cancers: From Clinical Practice to Ongoing Clinical Trials. Int J Mol Sci 2020;21:E4427. [PMID: 32580338 DOI: 10.3390/ijms21124427] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 8.0] [Reference Citation Analysis]
16 Sun H, Kim E, Ryu J, Lee H, Shin EA, Lee M, Lee H, Lee JH, Yoon JH, Song DG, Kim S, Lee JW. TM4SF5-mediated liver malignancy involves NK cell exhaustion-like phenotypes. Cell Mol Life Sci 2021. [PMID: 34921636 DOI: 10.1007/s00018-021-04051-x] [Reference Citation Analysis]
17 Deng M, Li S, Mei J, Lin W, Zou J, Wei W, Guo R. High SGO2 Expression Predicts Poor Overall Survival: A Potential Therapeutic Target for Hepatocellular Carcinoma. Genes (Basel) 2021;12:876. [PMID: 34200261 DOI: 10.3390/genes12060876] [Reference Citation Analysis]
18 Shojaie L, Ali M, Iorga A, Dara L. Mechanisms of immune checkpoint inhibitor-mediated liver injury. Acta Pharm Sin B 2021;11:3727-39. [PMID: 35024302 DOI: 10.1016/j.apsb.2021.10.003] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
19 He H, Lin X, Guo J, Wang J, Xu B. Perimitochondrial Enzymatic Self-Assembly for Selective Targeting the Mitochondria of Cancer Cells. ACS Nano 2020;14:6947-55. [PMID: 32383849 DOI: 10.1021/acsnano.0c01388] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 12.0] [Reference Citation Analysis]
20 Luo JP, Wang J, Huang JH. CDKN2A is a prognostic biomarker and correlated with immune infiltrates in hepatocellular carcinoma. Biosci Rep 2021;41:BSR20211103. [PMID: 34405225 DOI: 10.1042/BSR20211103] [Reference Citation Analysis]
21 Wu JY, Yin ZY, Bai YN, Chen YF, Zhou SQ, Wang SJ, Zhou JY, Li YN, Qiu FN, Li B, Yan ML. Lenvatinib Combined with Anti-PD-1 Antibodies Plus Transcatheter Arterial Chemoembolization for Unresectable Hepatocellular Carcinoma: A Multicenter Retrospective Study. J Hepatocell Carcinoma 2021;8:1233-40. [PMID: 34676181 DOI: 10.2147/JHC.S332420] [Reference Citation Analysis]
22 Galati G, Massimo Vainieri AF, Maria Fulgenzi CA, Di Donato S, Silletta M, Gallo P, Onorato A, Vespasiani-Gentilucci U, Picardi A. Current Treatment Options for HCC: From Pharmacokinetics to Efficacy and Adverse Events in Liver Cirrhosis. Curr Drug Metab 2020;21:866-84. [PMID: 32957880 DOI: 10.2174/1389200221999200918141239] [Reference Citation Analysis]
23 Yang Y, Ge H, Li DQ, Xu AX. E2F1-Induced lncRNA BAIAP2-AS1 Overexpression Contributes to the Malignant Progression of Hepatocellular Carcinoma via miR-361-3p/SOX4 Axis. Dis Markers 2021;2021:6256369. [PMID: 34616498 DOI: 10.1155/2021/6256369] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
24 Zhang W, Chen K, Tian W, Zhang Q, Sun L, Wang Y, Liu M, Zhang Q. A Novel and Robust Prognostic Model for Hepatocellular Carcinoma Based on Enhancer RNAs-Regulated Genes. Front Oncol 2022;12:849242. [PMID: 35646665 DOI: 10.3389/fonc.2022.849242] [Reference Citation Analysis]
25 Ahmed F, Onwumeh-Okwundu J, Yukselen Z, Endaya Coronel MK, Zaidi M, Guntipalli P, Garimella V, Gudapati S, Mezidor MD, Andrews K, Mouchli M, Shahini E. Atezolizumab plus bevacizumab versus sorafenib or atezolizumab alone for unresectable hepatocellular carcinoma: A systematic review. World J Gastrointest Oncol 2021; 13(11): 1813-1832 [PMID: 34853653 DOI: 10.4251/wjgo.v13.i11.1813] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
26 Miao L, Zhang Z, Ren Z, Li Y. Application of Immunotherapy in Hepatocellular Carcinoma. Front Oncol 2021;11:699060. [PMID: 34513678 DOI: 10.3389/fonc.2021.699060] [Reference Citation Analysis]
27 Wang L, Li B, Bo X, Yi X, Xiao X, Zheng Q. Hypoxia-induced LncRNA DACT3-AS1 upregulates PKM2 to promote metastasis in hepatocellular carcinoma through the HDAC2/FOXA3 pathway. Exp Mol Med 2022;54:848-60. [PMID: 35764883 DOI: 10.1038/s12276-022-00767-3] [Reference Citation Analysis]
28 Tan S, Song X, Zhang C, Sun Y, Zhang J, Zhang Z, Zhang R, Zhang T, Zhu X, Tan H, Wang F. hsa-miR-9-5p-Mediated TSPAN9 Downregulation Is Positively Related to Both Poor Hepatocellular Carcinoma Prognosis and the Tumor Immune Infiltration. Journal of Immunology Research 2022;2022:1-10. [DOI: 10.1155/2022/9051229] [Reference Citation Analysis]
29 Roderburg C, Özdirik B, Wree A, Demir M, Tacke F. Systemic treatment of hepatocellular carcinoma: from sorafenib to combination therapies. Hepat Oncol 2020;7:HEP20. [PMID: 32647565 DOI: 10.2217/hep-2020-0004] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 4.5] [Reference Citation Analysis]
30 Du X, Zhang Y. Integrated Analysis of Immunity- and Ferroptosis-Related Biomarker Signatures to Improve the Prognosis Prediction of Hepatocellular Carcinoma. Front Genet 2020;11:614888. [PMID: 33391356 DOI: 10.3389/fgene.2020.614888] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 3.5] [Reference Citation Analysis]
31 Wu M, Jiang L. Hydroxysteroid 17-Beta Dehydrogenase 6 Is a Prognostic Biomarker and Correlates with Immune Infiltrates in Hepatocellular Carcinoma. Dig Dis Sci 2021. [PMID: 33495920 DOI: 10.1007/s10620-021-06832-7] [Reference Citation Analysis]
32 Zheng L, Fang S, Wu F, Chen W, Chen M, Weng Q, Wu X, Song J, Zhao Z, Ji J. Efficacy and Safety of TACE Combined With Sorafenib Plus Immune Checkpoint Inhibitors for the Treatment of Intermediate and Advanced TACE-Refractory Hepatocellular Carcinoma: A Retrospective Study. Front Mol Biosci 2020;7:609322. [PMID: 33521054 DOI: 10.3389/fmolb.2020.609322] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
33 Pascut D, Pratama MY, Vo NVT, Masadah R, Tiribelli C. The Crosstalk between Tumor Cells and the Microenvironment in Hepatocellular Carcinoma: The Role of Exosomal microRNAs and their Clinical Implications. Cancers (Basel) 2020;12:E823. [PMID: 32235370 DOI: 10.3390/cancers12040823] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 6.5] [Reference Citation Analysis]
34 Liu HT, Jiang MJ, Deng ZJ, Li L, Huang JL, Liu ZX, Li LQ, Zhong JH. Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: Current Progresses and Challenges. Front Oncol 2021;11:737497. [PMID: 34745958 DOI: 10.3389/fonc.2021.737497] [Reference Citation Analysis]
35 Wang YB, Ma R, Wang ZB, Shi QL, Zhang L, Chen WZ, Gong JP, Bai J. Transcatheter Arterial Chemoembolization in Combination With High-Intensity Focused Ultrasound for Intermediate and Advanced Hepatocellular Carcinoma: A Meta-Analysis. Front Oncol 2022;12:797349. [PMID: 35419281 DOI: 10.3389/fonc.2022.797349] [Reference Citation Analysis]
36 Chen RY, Yen CJ, Lin YJ, Wang JM, Tasi TF, Huang YC, Liu YW, Tsai HW, Lee MH, Hung LY. CPAP enhances and maintains chronic inflammation in hepatocytes to promote hepatocarcinogenesis. Cell Death Dis 2021;12:983. [PMID: 34686650 DOI: 10.1038/s41419-021-04295-2] [Reference Citation Analysis]
37 Liu R, Jiang Z, Kong W, Zheng S, Dai T, Wang G. A Novel Nine-Gene Signature Associated With Immune Infiltration for Predicting Prognosis in Hepatocellular Carcinoma. Front Genet 2021;12:730732. [PMID: 34917126 DOI: 10.3389/fgene.2021.730732] [Reference Citation Analysis]
38 Zhao WT, Han LX, Liu L, Zeng BZ, Zhang Y, Zhao LF, Hu HY, Xia JW, Li YZ, Xiang XD, Lin XL, Lu D, Li GF. The Yunnan national medicine Maytenus compound inhibits the proliferation of hepatocellular carcinoma (HCC) by suppressing the activation of the EGFR-PI3K-AKT signaling pathway. J Cancer 2021;12:3325-34. [PMID: 33976742 DOI: 10.7150/jca.56426] [Reference Citation Analysis]
39 Hernández-Alvarez MI, Zorzano A. Mitochondrial Dynamics and Liver Cancer. Cancers (Basel) 2021;13:2571. [PMID: 34073868 DOI: 10.3390/cancers13112571] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
40 Hendrickson PG, Olson M, Luetkens T, Weston S, Han T, Atanackovic D, Fine GC. The promise of adoptive cellular immunotherapies in hepatocellular carcinoma.Oncoimmunology. 2020;9:1673129. [PMID: 32002284 DOI: 10.1080/2162402X.2019.1673129] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
41 Yu S, Wang Y, Hou J, Li W, Wang X, Xiang L, Tan D, Wang W, Jiang L, Claret FX, Jiao M, Guo H. Tumor-infiltrating immune cells in hepatocellular carcinoma: Tregs is correlated with poor overall survival.PLoS One. 2020;15:e0231003. [PMID: 32240238 DOI: 10.1371/journal.pone.0231003] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 4.5] [Reference Citation Analysis]
42 Liu Q, You N, Li J, Wu K, Peng X, Wang Z, Wang L, Zhu Y, Zheng L. Camrelizumab Plus Sorafenib Versus Sorafenib Monotherapy for Advanced Hepatocellular Carcinoma: A Retrospective Analysis. Front Oncol 2021;11:694409. [PMID: 34737945 DOI: 10.3389/fonc.2021.694409] [Reference Citation Analysis]
43 Ramos-Casals M, Brahmer JR, Callahan MK, Flores-Chávez A, Keegan N, Khamashta MA, Lambotte O, Mariette X, Prat A, Suárez-Almazor ME. Immune-related adverse events of checkpoint inhibitors. Nat Rev Dis Primers 2020;6:38. [PMID: 32382051 DOI: 10.1038/s41572-020-0160-6] [Cited by in Crossref: 98] [Cited by in F6Publishing: 113] [Article Influence: 49.0] [Reference Citation Analysis]
44 Chen R, Chen Y, Huang W, Zhao Y, Luo W, Lin J, Wang Z, Yang J. Comprehensive analysis of an immune-related ceRNA network in identifying a novel lncRNA signature as a prognostic biomarker for hepatocellular carcinoma. Aging (Albany NY) 2021;13:17607-28. [PMID: 34237706 DOI: 10.18632/aging.203250] [Reference Citation Analysis]
45 Zhang C, Yang M, Ericsson AC. The Potential Gut Microbiota-Mediated Treatment Options for Liver Cancer. Front Oncol 2020;10:524205. [PMID: 33163393 DOI: 10.3389/fonc.2020.524205] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
46 Sirohi B, Shrikhande SV, Gaikwad V, Patel A, Patkar S, Goel M, Bal M, Sharma A, Shrimali RK, Bhatia V, Kulkarni S, Srivastava DN, Kaur T, Dhaliwal RS, Rath GK; Indian Council of Medical Research Guidelines Working Group. Indian Council of Medical Research consensus document on hepatocellular carcinoma. Indian J Med Res 2020;152:468-74. [PMID: 33707388 DOI: 10.4103/ijmr.IJMR_404_20] [Reference Citation Analysis]
47 Sun K, Shi L, Qiu J, Pan Y, Wang X, Wang H. Multi-phase contrast-enhanced magnetic resonance image-based radiomics-combined machine learning reveals microscopic ultra-early hepatocellular carcinoma lesions. Eur J Nucl Med Mol Imaging 2022. [PMID: 35230493 DOI: 10.1007/s00259-022-05742-8] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
48 Wang J, Li J, Tang G, Tian Y, Su S, Li Y. Clinical outcomes and influencing factors of PD-1/PD-L1 in hepatocellular carcinoma. Oncol Lett 2021;21:279. [PMID: 33732355 DOI: 10.3892/ol.2021.12540] [Reference Citation Analysis]
49 Donisi C, Puzzoni M, Ziranu P, Lai E, Mariani S, Saba G, Impera V, Dubois M, Persano M, Migliari M, Pretta A, Liscia N, Astara G, Scartozzi M. Immune Checkpoint Inhibitors in the Treatment of HCC. Front Oncol 2020;10:601240. [PMID: 33585218 DOI: 10.3389/fonc.2020.601240] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
50 Oh S, Park Y, Lee HJ, Lee J, Lee SH, Baek YS, Chun SK, Lee SM, Kim M, Chon YE, Ha Y, Cho Y, Kim GJ, Hwang SG, Kwack K. A Disintegrin and Metalloproteinase 9 (ADAM9) in Advanced Hepatocellular Carcinoma and Their Role as a Biomarker During Hepatocellular Carcinoma Immunotherapy. Cancers (Basel) 2020;12:E745. [PMID: 32245188 DOI: 10.3390/cancers12030745] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
51 Zhao L, Chang N, Shi L, Li F, Meng F, Xie X, Xu Z, Wang F. Lenvatinib plus sintilimab versus lenvatinib monotherapy as first-line treatment for advanced HBV-related hepatocellular carcinoma: A retrospective, real-world study. Heliyon 2022;8:e09538. [PMID: 35706954 DOI: 10.1016/j.heliyon.2022.e09538] [Reference Citation Analysis]
52 Moawad AW, Szklaruk J, Lall C, Blair KJ, Kaseb AO, Kamath A, Rohren SA, Elsayes KM. Angiogenesis in Hepatocellular Carcinoma; Pathophysiology, Targeted Therapy, and Role of Imaging. J Hepatocell Carcinoma 2020;7:77-89. [PMID: 32426302 DOI: 10.2147/JHC.S224471] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
53 Dong X, Wang F, Liu C, Ling J, Jia X, Shen F, Yang N, Zhu S, Zhong L, Li Q. Single-cell analysis reveals the intra-tumor heterogeneity and identifies MLXIPL as a biomarker in the cellular trajectory of hepatocellular carcinoma. Cell Death Discov 2021;7:14. [PMID: 33462196 DOI: 10.1038/s41420-021-00403-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]